Q1 2024

Filed May 8, 2024 · 10-Q · 38 days after period end · 0000950170-24-055053

Q1 2024 · 10-Q

Revenue

$0.00

no prior Q1 2023 on file

Net Income

-$72.40M

N/M vs Q1 2023

EPS Diluted

-$0.85

N/M vs Q1 2023

Operating Income-$79,514,000N/M

Operating Cash Flow

Same quarter

Metric	Q1 2024	Q1 2023	Q1 2022	Q1 2021
Revenue	$0.00	—	—	$379.00K
Net Income	-$72.40M	-$41.13M	-$37.17M	-$27.72M
EPS Diluted	-$0.85	-$0.59	-$0.63	-$0.54

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR